230 related articles for article (PubMed ID: 35970919)
1. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
Chatila WK; Kim JK; Walch H; Marco MR; Chen CT; Wu F; Omer DM; Khalil DN; Ganesh K; Qu X; Luthra A; Choi SH; Ho YJ; Kundra R; Groves KI; Chow OS; Cercek A; Weiser MR; Widmar M; Wei IH; Pappou EP; Nash GM; Paty PB; Shi Q; Vakiani E; Duygu Selcuklu S; Donoghue MTA; Solit DB; Berger MF; Shia J; Pelossof R; Romesser PB; Yaeger R; Smith JJ; Schultz N; Sanchez-Vega F; Garcia-Aguilar J
Nat Med; 2022 Aug; 28(8):1646-1655. PubMed ID: 35970919
[TBL] [Abstract][Full Text] [Related]
2. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
3. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
4. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
5. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
6. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital.
Yeung WW; Ma BB; Lee JF; Ng SS; Cheung MH; Ho WM; Tsang MW; Chu S; Lam DC; Mo FK
Hong Kong Med J; 2016 Dec; 22(6):546-55. PubMed ID: 27795447
[TBL] [Abstract][Full Text] [Related]
8. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.
Ho SSK; Hon SSF; Hung E; Lee JFY; Mo F; Tong M; So C; Chu S; Ng DCK; Lam D; Cho C; Mak TWC; Ng SSM; Futaba K; Suen J; To KF; Chan AWH; Yeung WWK; Ma BBY
Hong Kong Med J; 2022 Jun; 28(3):230-238. PubMed ID: 35667869
[TBL] [Abstract][Full Text] [Related]
11. Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review.
He W; Li Q; Li X
Crit Rev Oncol Hematol; 2023 Jan; 181():103885. PubMed ID: 36464124
[TBL] [Abstract][Full Text] [Related]
12. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
14. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
16. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
17. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
18. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
19. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Gómez Del Pulgar T; Cebrián A; Fernández-Aceñero MJ; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Marín-Arango JP; Caramés C; Vega-Bravo R; Rodríguez-Remírez M; Cruz-Ramos M; Manzarbeitia F; García-Foncillas J
J Cell Mol Med; 2016 Sep; 20(9):1729-36. PubMed ID: 27171907
[TBL] [Abstract][Full Text] [Related]
20. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer.
Sun Z; Adam MA; Kim J; Turner MC; Fisher DA; Choudhury KR; Czito BG; Migaly J; Mantyh CR
Colorectal Dis; 2017 Dec; 19(12):1058-1066. PubMed ID: 28586509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
